v3.25.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash flows from operating activities:    
Net loss $ (709,555) $ (971,322)
Stock-based compensation expense included in -    
Research and development costs
General and administrative costs 99,738 102,927
Increase in -    
Prepaid insurance 3,813 (5,678)
Other prepaid expenses (26,793) (64,130)
Accounts payable and accrued expenses 56,770 89,929
Research and development contract liabilities 7,544 59,049
Net cash used in operating activities (568,483) (789,225)
Cash flows from financing activities:    
Proceeds from sale of securities in registered direct offering, net of offering costs 914,228
Net cash provided by financing activities 914,228
Cash:    
Net increase (decrease) 345,745 (789,225)
Balance at beginning of period 1,038,952 4,203,488
Balance at end of period 1,384,697 3,414,263
Supplemental disclosures of cash flow information:    
Interest 3,135 7,186
Income taxes
Settlement of accrued compensation to Board of Directors by issuance of stock options $ 27,500

Source

HTML PDF
ZIP